BCDA (BioCardia, Inc) Return on Sales by Gross Profit

Corporate emblem and logo of BioCardia Inc. (BCDA)

The financial position of BioCardia, Inc. (BCDA) relies on raised capital, as commercial products have not yet entered the market. The relative gross margin reflects profitability trends, where 0.00 shows the current value of the metric. Risk mitigation is achieved through the testing of cell systems across various cardiological profiles, although the cost of cryogenic air delivery for biomaterials significantly increases the company's operating expenses.

BCDA - BioCardia Gross Margin over the range 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for BioCardia, Inc. (BCDA)

Fundamental valuation:BCDA, BioCardia
Mass-produced product of BioCardia Inc

For BioCardia, Inc. (BCDA), gross margin serves as an indicator of efficiency in covering direct costs associated with cell therapy development. This metric measures the portion of revenue remaining after deducting the cost of goods sold, allowing for an assessment of the fundamental profitability of each product unit. An analysis of gross margin stability confirms that the issuer's current financial performance depends entirely on clinical trial outcomes and future market approval.